Clinical Cancer Research · 2023 · 27 citations · 39 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune Checkpoint RegulationPancreatic CancerAdaptive Antitumor ImmunityCtla-4 InhibitionImmune Checkpoint Inhibitor TherapyNeoadjuvant ChemoradiationNf-κb SignalingPd-l1 BlockadeT Cell Checkpoint InhibitionT-cell Mediated Responses
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) trials have evaluated CTLA-4 and/or PD-(L)1 blockade in patients with advanced disease in which bulky tumor burden and limited time to develop antitumor T cells may have contributed to poor clinical efficacy. Here, we evaluated peripheral blood and tumor T cells from patients with PDAC receiving neoadjuvant chemoradiation plus anti-PD-1 (pembrolizumab) versus chemoradiation alone. We analyzed whether PD-1 blockade successfully reactivated T cells in the blood and/or tumor to determine whether lack of clinical benefit could be explained by lack of reactivated T cells versus other factors. EXPERIMENTAL DESIGN: We used single-cell transcriptional profiling and TCR clonotype tracking to identify TCR clonotypes from blood that match clonotypes in the tumor. RESULTS: PD-1 blockade increases the flux of TCR clonotypes entering cell cycle and induces an IFNγ signature like that seen in patients with other GI malignancies who respond to PD-1 blockade. However, these reactivated T cells have a robust signature of NF-κB signaling not seen in cases of PD-1 antibody response. Among paired samples between blood and tumor, several of the newly cycling clonotypes matched activated T-cell clonotypes observed in the tumor. CONCLUSIONS: Cytotoxic T cells in the blood of patients with PDAC remain sensitive to reinvigoration by PD-1 blockade, and some have tumor-recognizing potential. Although these T cells proliferate and have a signature of IFN exposure, they also upregulate NF-κB signaling, which potentially counteracts the beneficial effects of anti-PD-1 reinvigoration and marks these T cells as non-productive contributors to antitumor immunity. See related commentary by Lander and DeNardo, p. 474.
39
Aurélien Marabelle, Dung T. Le, Paolo A. Ascierto et al. · Journal of Clinical Oncology · 2019 · 3K citations · Full text
Life Sciences, Immunology, Oncology +17
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Se Jin Im, Masao Hashimoto, Michael Y. Gerner et al. · Nature · 2016 · 2.1K citations · Full text
Clonal replacement of tumor-specific T cells following PD-1 blockade
Kathryn E. Yost, Ansuman T. Satpathy, Daniel K. Wells et al. · Nature Medicine · 2019 · 1.5K citations